TY  - JOUR
AU  - Peters, Solange
AU  - Stahel, Rolf A
AU  - Dafni, Urania
AU  - Ponce Aix, Santiago
AU  - Massutí, Bartomeu
AU  - Gautschi, Oliver
AU  - Coate, Linda
AU  - López Martín, Ana
AU  - van Heemst, Robbert
AU  - Berghmans, Thierry
AU  - Meldgaard, Peter
AU  - Cobo Dols, Manuel
AU  - Garde Noguera, Javier
AU  - Curioni-Fontecedro, Alessandra
AU  - Rauch, Daniel
AU  - Mark, Michael T
AU  - Cuffe, Sinead
AU  - Biesma, Bonne
AU  - van Henten, Arjen M J
AU  - Juan Vidal, Óscar
AU  - Palmero Sanchez, Ramón
AU  - Villa Guzmán, José Carlos
AU  - Collado Martin, Ricardo
AU  - Peralta, Sergio
AU  - Insa, Amelia
AU  - Summers, Yvonne
AU  - Láng, István
AU  - Horgan, Anne
AU  - Ciardiello, Fortunato
AU  - de Hosson, Sander
AU  - Pieterman, Remge
AU  - Groen, Harry J M
AU  - van den Berg, Paul M
AU  - Zielinski, Christoph C
AU  - Chittazhathu Kurian Kuruvilla, Yojena
AU  - Gasca-Ruchti, Adriana
AU  - Kassapian, Marie
AU  - Novello, Silvia
AU  - Torri, Valter
AU  - Tsourti, Zoi
AU  - Gregorc, Vanesa
AU  - Smit, Egbert F
AU  - EMPHASIS-lung Collaborative Group
PY  - 2016
DO  - 10.1016/j.jtho.2016.12.017
UR  - http://hdl.handle.net/10668/10713
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - Docetaxel and erlotinib are registered second-line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second-line therapy of NSCLC, classifying patients as either VeriStrat good or VeriStrat...
LA  - en
KW  - Docetaxel
KW  - ETOP
KW  - Erlotinib
KW  - NSCLC
KW  - Squamous
KW  - VeriStrat
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Carcinoma, Squamous Cell
KW  - Cohort Studies
KW  - Docetaxel
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Neoplasm Staging
KW  - Platinum
KW  - Prognosis
KW  - Survival Rate
KW  - Taxoids
TI  - Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
TY  - research article
VL  - 12
ER  -